EP3618803A1 - Solution ophtalmique aqueuse stérile contenant du n-(n-acétylcystéinyl)-chitosane pour le traitement de troubles de la cornée non infectieux - Google Patents

Solution ophtalmique aqueuse stérile contenant du n-(n-acétylcystéinyl)-chitosane pour le traitement de troubles de la cornée non infectieux

Info

Publication number
EP3618803A1
EP3618803A1 EP18722034.8A EP18722034A EP3618803A1 EP 3618803 A1 EP3618803 A1 EP 3618803A1 EP 18722034 A EP18722034 A EP 18722034A EP 3618803 A1 EP3618803 A1 EP 3618803A1
Authority
EP
European Patent Office
Prior art keywords
period
days
length
solution
chitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18722034.8A
Other languages
German (de)
English (en)
Inventor
Martin Prinz
Sonja HÖLLER
Margit Hornof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Croma Pharma GmbH
Original Assignee
Croma Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Croma Pharma GmbH filed Critical Croma Pharma GmbH
Publication of EP3618803A1 publication Critical patent/EP3618803A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Definitions

  • the present invention relates to the therapeutic use of a sterile ophthalmic solution comprising N-(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution for use in treatment and prevention of non-infectious corneal disorders, in particular dry eye diseases and corneal epithelial defects.
  • Non-infectious corneal disorders can be related to a dysfunctional and/or instable tear film (e.g. lack of tear production, excessive tear production, increased tear evaporation) and/or corneal epithelial defects.
  • a dysfunctional and/or instable tear film e.g. lack of tear production, excessive tear production, increased tear evaporation
  • corneal epithelial defects e.g. corneal epithelial defects
  • DED Dry eye diseases
  • Several conditions affect the quality and stability of the tear film, which results in dry eye signs and symptoms and also negatively influence tear film functionality and frequently cause (temporary or chronic) dry eye diseases.
  • dry eye disease Among the indications that are referred to by the general term “dry eye disease” are:
  • Keratoconjunctivitis sicca Keratoconjunctivitis sicca (KCS), age-related dry eye, Stevens-Johnson syndrome, Sjogren's syndrome, ocular cicatrical pemphigoid, corneal injury, ocular surface infection, Riley-Day syndrome, congenital alacrima, nutritional disorders or deficiencies (including vitamin deficiencies), pharmacologic side effects, glandular and tissue destruction, autoimmune and other immunodeficient disorders, and inability or limitation to blink (e.g. in comatose patients or patients with Parkinson's disease). Also included are dry eye symptoms caused by environmental exposure to airborne particulates, smoke, smog, and excessively dry air; as well as contact lens intolerance and eye stress caused by computer work or computer gaming.
  • corneal epithelial defects Another subclass of non-infectious corneal disorders may be classified as corneal epithelial defects and damages.
  • Mechanical corneal injuries are the most common ophthalmic injuries. They are often caused by the impact of external physical forces (e.g. branches, finger nails, make up applicators), which results in damage of small or large parts of the corneal surface.
  • Foreign body-related abrasions are typically caused by pieces of airborne debris (such as pieces of metal, wood, glass, etc.) that have become embedded in the cornea. After removal of the foreign body defects in the corneal epithelium are left behind.
  • Contact lens-related abrasions are defects in the corneal epithelium which are caused by contact lens overuse or the wearing of an improperly fitting, or improperly cleaned contact lens. Chemical corneal injuries are another reason for corneal trauma. Exposure to alkaline or acidic substances can cause extensive damage to the corneal surface.
  • Corneal epithelial damage also occurs as a result of intense exposure to ultraviolet light (photokeratitis) due to the failure to use adequate eye protection (e.g. snow blindness).
  • Corneal wounds also occur in consequence of surgery, such as cataract surgery, corneal transplantation, glaucoma filtering surgery, and refractive eye surgery, such as
  • Recurrent corneal erosions are characterised by repeated episodes of corneal epithelial breakdown. They can be caused by corneal dystrophies such as epithelial basement membrane dystrophy or they can be the result of corneal minor trauma or abrasion (Steele, Chris, 1999, The role of therapeutic contact lenses in corneal wound healing, Optometry today (October 8): 36-40). The breakdown or loss of the epithelial layer leads to failures in the corneal surface integrity. Corneal wounds related to corneal erosions are thus mainly epithelial damages.
  • Epithelial defects that do not heal over a period of one or two weeks or heal and break down repeatedly are for example non-healing corneal epithelial defects, persistent corneal epithelial defects, slow-healing corneal epithelial defects, and neuropathic (neurotrophic) epithelial defects.
  • SPK superficial punctate keratitis
  • This corneal inflammation may be a result of various causes such as viral conjunctivitis (most commonly adenovirus), blepharitis, keratoconjunctivitis sicca, trachoma, chemical burns, ultraviolet (UV) light exposure (e.g. welding arcs, sunlaps, snow glare), contact lens overwear, systemic drugs (e.g. adenine arabinoside), topical drugs or preservation toxicity, and peripheral facial nerve palsy (including Bell's palsy).
  • UV ultraviolet
  • the SPK may be caused by infections as well as non-infectious reasons.
  • polymers have been disclosed as possible aids in providing some benefit to alleviating DED symptoms and the treatment of non-infectious corneal epithelial defects and damages and in fact some artificial tears contain one or more polymers, including the currently top 5 best selling over-the-counter (OTC) products for dry eye within the EU (Celluvisc®, Systane®, Hylo-Comod®, Optive® and Artelac®). These polymers are intended to protect ocular mucous membranes and provide lubrication for the ocular surface. Examples include cellulose derivatives, hyaluronic acid, liquid polyols, polyvinyl alcohol, povidone, carbopol and hydroxypropyl-guar.
  • OTC over-the-counter
  • Polymers used in products to treat DED have relatively short residence time on the ocular surface and require frequent instillation.
  • some formulations contain petroleum jelly or mineral oil; however, due to significant blurring these highly viscous products can only be used in the evening prior to sleep (Abelson et al., 2008, Tear Substitutes. In: Albert and Miller, eds. Principles and Practices of Ophthalmology, 3rd edition, vol.1. Philadelphia: W.B. Saunders Company, 287-292). All other tear substitutes have to be instilled repeatedly during the day. Some potential improvements to these polymers have been disclosed.
  • Chitosan a polycationic polymer which is derived from the natural polymer chitin, is well known for its mucoadhesive properties.
  • Ocular residence time of ophthalmic formulations containing chitosan can be increased not only due to its viscosity enhancing properties but also because of interactions of chitosan with negatively charged mucins on the ocular surface (Wadhwa, Paliwal et al., 2009, Chitosan and its role in ocular therapeutics, Mini Rev Med Chem (9): 1639-1647).
  • chitosan has antimicrobial activity against various pathogenic microorganisms (Felt, Carrel et al., 2000, Chitosan as tear substitute: a wetting agent endowed with antimicrobial efficacy, J Ocul Pharmacol Ther (16): 261-270; Dai, Tanaka et al., 2011, Chitosan preparations for wounds and burns:
  • a 1% solution of chitosan failed to improve corneal wound healing when applied three times a day for 3 weeks in a study using a rabbit model (Sail, Kreter et al., 1987, The effect of chitosan on corneal wound healing, Ann Ophthalmol (19): 31-33).
  • Another research group reported that 0.5% solutions of chitosan stimulated corneal wound healing after 24h incubation of rabbit corneas in organ culture (Cui et al., 2014, Chitosan promoted the corneal epithelial wound healing via activation of ERK MAPK Pathway, Invest. Ophthalmol. Vis. Sci. 55(13):499).
  • WO 2011/127144 discloses the use of derivatized chitosans for a number of different wound healing applications, including the use of a chitosan-arginine polymer for the treatment of corneal wounds.
  • a formulation containing a chitosan-arginine derivative for 9 days decreased inflammation and accelerated wound healing.
  • EP 1126881 Bl discloses a mucoadhesive polymer comprising at least one non-terminal thiol group.
  • the use of thiolated polysaccharides for preparing an implant for tissue augmentation is disclosed in WO 2008/077172, wherein said thiolated polymers are characterised by the formation of disulfide bonds which leads to a stabilisation of the polymeric network.
  • the priority application of WO 2008/077172, AT A 2136/2006 discloses further application fields for thiolated polymers.
  • NAC N- acetylcysteine
  • L-cysteine NAC
  • NAC NAC
  • NAC is a reducing agent with antioxidative activity. It is also well known for its ability to reduce mucus viscosity by reducing mucin disulfide bonds. Due to these mucolytic properties NAC is widely used to reduce mucus viscosity in broncho-pulmonary disorders with excessive mucus production.
  • Topical ophthalmic formulations containing the mucolytic and antioxidant agent NAC are used for the treatment of corneal diseases such as meibomian gland dysfunction and DED (Lemp, 2008, Management of dry eye disease, Am J Manag Care (14): S88-101; Akyol-Salman, Azizi et al., 2010, Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction, J Ocul Pharmacol Ther (26): 329-333).
  • EP 0 551 848 Bl discloses an ophthalmic pharmaceutical composition for the treatment of DED containing NAC in a concentration between 3% and 5% (w/v) and polyvinylalcohol.
  • N-(N-acetylcysteinyl-)chitosan HC1 has some beneficial effect on the ocular surface of the mouse eye in mouse dry eye models (Hongyok, Chae et al., 2009, Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B- induced dry eye, Arch Ophthalmol (127): 525-532; Hornof, Goyal et al., 2009, Thiolated Chitosan for the Treatment of Dry Eye - Evaluation in Mice Using the Controlled- Environment Chamber Model, ARVO Meeting Abstracts (50): 3663).
  • WO 2015/169728 discloses a sterile aqueous ophthalmic solution comprising about 0.05% to about 0.5% (w/w) of N-(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N-(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ⁇ /g polymer to 280 ⁇ /g polymer, and the use of said solution for the treatment of DED.
  • Beneficial effects of the chitosan-NAC solution on corneal wound healing has been identified previously (WO 2017/072236).
  • the aqueous ophthalmic solution is applied once or twice a day.
  • composition suitable for the prevention or treatment of non-infectious corneal disorders, in particular dry eye diseases or persistent corneal epithelial defects with manageable and improved therapeutic use.
  • the present invention provides a sterile aqueous ophthalmic solution comprising N-(N- acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N-(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ⁇ /g polymer to 280 ⁇ /g polymer, for the specific use in the prevention or treatment of a non-infectious corneal disorder, in particular a dry eye disease or a persistent corneal epithelial defect, wherein said solution is applied intermittently with a period A during which period A said solution is applied and wherein the length of period A is 5 or more subsequent days, and with a period B following said period A during which period B application of said solution is ceased, and wherein the length of period B is at least 2 subsequent days and at most 180 subsequent days and with a period C following said period B during which period C said solution is applied and wherein the length of period
  • the present invention provides a method of treatment or prevention of a subject with a non-infectious corneal disorder, in particular a dry eye disease or a persistent corneal epithelial defect, wherein a sterile aqueous ophthalmic solution comprising N-(N- acetylcysteinyl-)chitosan as defined above, is applied intermittently with a period A during which period A said solution is applied and wherein the length of period A is 5 or more subsequent days, and with a period B following said period A during which period B application of said solution is ceased, and wherein the length of period B is at least 2 subsequent days and in particular at most 180 subsequent days and with a period C following said period B during which period C said solution is applied and wherein the length of period C is 1 or more day(s).
  • a sterile aqueous ophthalmic solution comprising N-(N- acetylcysteinyl-)chitosan as defined above
  • chitosan-NAC stands for both N-(N-acetylcysteinyl-)chitosan and pharmaceutically acceptable salts thereof.
  • a sterile aqueous ophthalmic solution comprising N-(N- acetylcysteinyl-)chitosan showed a long-lasting positive effect even after interruption of the treatment.
  • dry eye signs such as tear film break up time
  • dry eye symptoms such as ocular discomfort
  • the long-lasting effect may be due to the mucoadhesive properties, the extent of which is surprisingly high and consequently long ocular residence time for the sterile ophthalmic chitosan-NAC solution and its ability to form a durable protective coating on the ocular surface and to stabilize the tear film.
  • Advantages of the intermittent administration regime according to the invention are numerous and may include for example increased patient compliance, reduced side effect (e.g. reduced risk of infection by improper application of the solution), avoidance of tolerance effect, and so on.
  • the intermittent administration regime according to the present invention includes two types of time periods, i.e. one wherein the chitosan-NAC solution is applied (period A and C) and another one, wherein the chitosan-NAC solution is not applied, i.e. wherein the application is paused (period B, optionally period B' as discussed below).
  • Period A refers to a time period, wherein the use according to the present invention is initiated.
  • Period B refers to a time period, wherein no solution is applied and the first period B directly follows period A.
  • period C a further period of applying the chitosan-NAC solution follows.
  • Any period of the use or method according to the invention has a length, said length is typically expressed in days or weeks. When it is indicated that a period is having x day(s), this is synonym to the length of said period being x day(s).
  • a reference to x days is to be understood as x subsequent days.
  • the administration regime according to the invention previews that the period A has at least 5 days and the period B has 2 to 180 days.
  • the length of the period B is dependent on the length of the initial period A and this dependence may expressed according to the following equation I :
  • the ratio of both lengths depends on the factor f, which was identified to be within the range of 0.2 to 36.
  • Factor f may be any real number in the specified range, and accordingly also the result of the multiplication may be a non-natural number.
  • a and B should be natural numbers (positive integers) to indicate a reasonable time period A or B in full days.
  • the length of period B in days is obtained by multiplying A with f and in case the result is no integer, it is rounded up to the next natural number. This is also indicated by the ceiling function in equation I. Also in this embodiment, the provision applies that the length of period B is at least 2 and that period B does not extend 180 days.
  • the length of period B is in the range of 5 to 90 days.
  • f is at least 1, thus the period B is at least as long as period A.
  • the factor f may further depend on the length of period A according to the following provisions
  • length of period A is in the range of from 5 to 10 days
  • f is in the range of from 0.4 to 36, preferably 1 to 18, more preferably 1 to 9,
  • length of period B is in the range of from 2 to 180 days, preferably 5 to 180 days, more preferably 5 to 90 days;
  • length of period A is in the range of from 11 to 14 days
  • f is in the range of from 0.3 to 17, preferably 0.4 to 8, more preferably 0.4 to 4,
  • length of period B is in the range of from 4 to 180 days, preferably 5 to 112 days, more preferably 5 to 56 days;
  • length of period A is in the range of from 15 to 29 days
  • f is in the range of from 0.3 to 12, preferably 0.3 to 6, more preferably 0.3 to 3,
  • length of period B is in the range of from 5 to 180 days, preferably 5 to 174, more preferably 5 to 87 days;
  • length of period A is in the range of from 30 to 42 days
  • f is in the range of from 0.2 to 6, preferably 0.2 to 3, more preferably 0.2 to 1.5
  • length of period B is in the range of from 6 to 180 days, preferably 6 to 126 days, more preferably 6 to 63 days.
  • Preferred length of C > 5 > 0.7 0.2 to 2 to 180 0.3 to 1 to 30
  • Exemplary embodiment 2 7 1.0 0.4 3 0.4 1, 2, 5,
  • Exemplary embodiment 3 10 10 1.4 12 120 17.1 5, 7 or
  • Exemplary embodiment 4 7 to 42 1 to 6 2 14 to 84 2 to 12 7 to 14
  • Exemplary embodiment 5 30 4.3 0.92 to 28 to 31 4 to 4.4 1
  • Exemplary embodiment 8 5 0.7 0.4 to 2 to 4 0.29 - 1
  • Exemplary embodiment 9 5 0.7 0.6 3 0.42 1
  • period C After intermittence period B, use of the ophthalmic solution is continued during a further period of application (period C).
  • the application during period C may be considered as maintenance dosage to refresh the therapeutic effect established in period A.
  • period C may be a short period, i.e. a period with few applications or even one application of the chitosan-NAC solution is sufficient.
  • the length of period C in day(s) is 1 or more.
  • the length of period C is in the range of 1 to 42 days, more preferably the length of period C is in the range of 1 to 30 days or in the range of 1 to 21 days. Even more preferably, the length of period C is in the range of 1 to 10 days or 1 to 5 days.
  • Exemplarily period C is 1, 2, 5, 7 or 10 days.
  • the length of period C is substantially shorter than that of period A.
  • the present invention defines a sequence of two periods, which sequence comprises a period B', during which period B' application of said solution is ceased, and a period C, during which period C said solution is applied.
  • the intermittent application for use according to the invention includes a sequence following period C, wherein the sequence is comprising a period B', during which period B' application of said solution is again ceased, and a period C, during which period C said solution is applied.
  • this sequence (comprising a period B' and a period C) is repeated at least once.
  • period B' no applying
  • period C applying
  • the sequence of period B' (no applying) and period C (applying) may be repeated for continued treatment after the initial period A.
  • the period C is followed by a further treatment pause of period B' and a further period C of application, and so on.
  • each period B or B' and any following periods, wherein said ophthalmic solution is not applied, may be considered as structured/strategic treatment interruption or drug/medicament vacation/holiday.
  • period B' is as long as period B or longer.
  • any interval of non-application (period B and period(s) B') has the same length.
  • period(s) C is/are as long as period C or longer, wherein the length of the period(s) is at least one day.
  • period B is/are 27 to 30 and each period C/C is one day.
  • Such an application scheme may be considered convenient as the last day of period A (for example 15 th of May), may form a basis for easy calculation of any further application.
  • the next application is due on the day in the relevant subsequent month, which has the same number as the day on which the period A was stopped (e.g. 15 th of June). If the relevant subsequent month has no day with the same number, the period B or B' ends before the last day of that month.
  • the length of the period B or B' depends on the length of the relevant month and ranges between 27 and 30 days (s. exemplary embodiment 5 in Table 1).
  • a 28-day rhythm might underlie the sequences of period B and C. This is for example the case, wherein after an initial treatment period A, the application is ceased for 3 weeks and then the application is resumed for 1 week, followed again by 3 weeks of non- application and one week of application, and so on.
  • Embodiments with a 28-day rhythm might be preferred in subjects familiar with a 28-day rhythm, e.g. women taking oral contraceptives.
  • a shorter rhythm might underlie the sequences of periods B/B' and C/C. This is shown in the exemplary embodiment 8 or 9 according to table 1.
  • the application is repeated every third to fifth day, i.e. ceased for period B of 2 to 4 days and then the application period C is one day, and so on.
  • a sustained therapeutic effect could be obtained for example with a regime, wherein the solution was applied every third to fourth day, while the application effort was kept at a low and convenient level as shown in Example 6 below.
  • the periods are repeated to obtain a longer overall treatment period (first day of period A to last day of last period C).
  • the overall treatment period may be several months, e.g. sequences of periods B' and C are repeated to obtain an overall treatment period of about 4, 6, 9 or 12 months.
  • the following information on administering or applying the chitosan-NAC solution may apply for the period A as well as any following period C or period(s) C of applying the ophthalmic solution for use according to the invention. If treatment or prevention is intended for both eyes, any formulation as used herein should be understood as "per eye”.
  • the application of the chitosan-NAC in period A or C includes applying the solution as eye drops at least once daily, e.g. once or twice. In a preferred embodiment during period A, during period C and/or during optional period(s) C, the ophthalmic solution for use according to the present invention is applied once daily.
  • chitosan-NAC solution is especially beneficial if said ophthalmic solution is applied prior to sleep (WO 2017/072235).
  • the ophthalmic solution for use according to the present invention is applied prior to sleep.
  • the wording "prior to sleep” refers to an application before going to sleep.
  • “Sleep” refers to a periodic physiological loss of consciousness. By “periodic” it is understood to mean a substantially uniform repeating pattern. For example, an adult may sleep approximately 8 hours per day.
  • the application prior to sleep covers also the application at a time point prior to a period of night's rest or state of calm independent of loss of consciousness. With other words, the application is preferred before going to bed with the intention to sleep. Synonym terms could be "omne nocte on", a Latin term for "every night", or “hora somni”, Latin for "at the hour of sleep”. Thus, the application is preferred at bedtime. In context of the present invention it is preferred that the medication is applied immediately before going to sleep.
  • the wording used for instructing the application refers to going "to sleep” rather than going "to bed” as activities like reading or watching TV or the like should not be encouraged between application and the effective sleep.
  • the ophthalmic solution for use according to the invention is applied 1 hour before to immediately prior to sleep, more preferably immediately prior to sleep.
  • the ophthalmic solution for use according to the present invention is applied once per day prior to sleep.
  • the present invention is suitable for treatment and prevention of a non-infectious corneal disorder. It is expected that treatment and prevention of non-infectious corneal disorders profit from the long-lasting tear film stabilisation and protective coating on the ocular surface of the use according to the present invention.
  • the use according to the present invention is expected to be especially beneficial for prevention and treatment of noninfectious corneal disorders related to a dysfunctional tear film (e.g. lack of tear production, excessive tear production, increased tear evaporation, decreased tear film stability) and persistent corneal epithelial defects and damages.
  • the noninfectious corneal disorder is a persistent corneal epithelial defect or a dry eye disease. It should be noted that corneal wounds are frequently accompanied by dry eye symptoms and vice versa.
  • the chitosan-NAC solution is used for the treatment or prevention of a dry eye disease, wherein this term includes dry eye syndrome as well as dry eye signs and/or symptoms.
  • dry eye syndrome or “dry eye disease” as pertaining to the present invention can be any syndrome associated with tear film instability and/or dysfunction (such as increased tear evaporation and/or reduced aqueous secretion).
  • the present invention i.e. the ophthalmic solution for use in treatment or prevention, is especially beneficial for those, wherein the dry eye disease is moderate to severe and/or chronic and who experience frequent or constant ocular discomfort.
  • the dry eye disease has a dry eye severity level of 2 to 4, preferably 3 to 4.
  • the dry eye disease is chronic.
  • chronic dry eye disease refers to a condition, wherein the dry eye disease is persistent or (re)occurring regularly, i.e. not temporary.
  • the chitosan-NAC solution is used for the treatment or prevention, in particular the treatment, of a corneal epithelial defect.
  • the invention is useful in context of a persistent corneal epithelial defect.
  • a persistent corneal epithelial defect occurs when corneal re-epithelialization does not take place within the normal two-week time frame or the corneal epithelium heals and breaks down repeatedly (e.g. recurrent corneal erosions).
  • the present invention is suitable for use in treatment and prevention of a noninfectious disorder, wherein the non-infectious corneal disorder is associated with a diagnose selected out of the group consisting of age related dry eye; congenital alacrima; Riley Day syndrome (familial dysautonomia); sarcoidosis, lymphoma, AIDS, Graft vs host disease (result in lacrimal gland deficiencies); chemical and thermal burns, erythema multiforme, cicatricial pemphigoid and mucous membrane pemphigoid, trachoma (lead to lacrimal gland duct obstruction); damage of corneal, conjunctival and/or lid tissue, of lacrimal glands, of lacrimal ducts; menopause; autoimmune diseases which affect the ocular surface: such as Sjogren Syndrome, rheumatoid arthritis, systemic lupus erythematosis, polyarteritis nodosa, Wegener'
  • chronic glaucoma treatment and preservatives; chronic contact lens wear; chronic allergic conjunctivitis; non-healing corneal epithelial defects, persistent corneal epithelial defects, slow-healing corneal epithelial defects, and neuropathic (neurotrophic) epithelial defects; corneal transplantation; limbal stem cell deficiency; laser eye surgery (especially laser assisted vision correction procedures such as photorefractive keratectomy (PRK), laser- assisted sub-epithelial keratectomy (LASEK) and laser-assisted in situ keratomileusis (LASIK)); Stevens- Johnson-Syndrome; recurrent corneal erosions; superficial punctate keratitis (SPK); glaucoma; surgical lesions.
  • PRK photorefractive keratectomy
  • LASEK laser- assisted sub-epithelial keratectomy
  • LASIK laser-assisted in situ keratomileusis
  • SPK superficial punctate ker
  • the N-(N-acetylcysteinyl-)chitosan or pharmaceutically acceptable salt thereof in said solution for use according to the present invention has a content of free thiol groups in an amount of from 105 ⁇ /g polymer to 250 ⁇ /g polymer, preferably of from 110 ⁇ /g polymer to 250 ⁇ /g polymer, most preferably of from preferably 140 to 250 ⁇ /g polymer.
  • the concentration of the N-(N- acetylcysteinyl-)chitosan or said pharmaceutically acceptable salt thereof in said solution is from 0.05 to 0.3% (w/w), preferably from 0.05 to 0.2% (w/w), more preferably 0.08 - 0.16% (w/w).
  • said pharmaceutically acceptable salt is selected from the group consisting of salts of organic acids such as acetic, citric, formic and tartaric acid, and salts of mineral acids such as HC1 and H2SO4.
  • Example 1 case study in a patient with dry eye syndrome (reference example)
  • a female patient of 77 years diagnosed with dry eye syndrome (no superficial punctate keratitis; SPK) presented with tearing eyes as well as tearfilm break up time of 3 seconds (right eye), and 5 seconds (left eye).
  • Use of a sodium hyaluronate based lubricant (Hylo-Gel) as needed represented the established therapeutic regime.
  • an aqueous ophthalmic solution with a pH of 6.3 comprising 0.1% w/w chitosan-NAC with a degree of modification of 210 ⁇ free thiol groups / g polymer, polyethylenglycol 40, hydroxypropyl methylcellulose and mannitol in a boric acid buffer was started.
  • the symptoms were improved.
  • the eye examination revealed no SPK and tearfilm break up time for both eyes was 10 sec. Medication with Hylo- Gel as needed and the chitosan-NAC solution was continued.
  • Example 2 case study in a patient with dry eye syndrome and SPK (reference example) A female patient (48 years old) presented with severe dry eye symptoms. The examination revealed superficial punctate keratitis (lower third of the cornea) as well as tear film break up time of 3 sec (right eye) and 10 sec (left eye). The patient already used artificial tears (HyloComod, Systane balance), when needed (at least 6 times a day).
  • Example 3 case study in a patient with dry eye syndrome
  • a female patient of 70 years diagnosed with dry eye syndrome presented with burning eyes, blurred vision and foreign body sensation.
  • the examination revealed superficial punctate keratitis (SPK) in the lower third of the cornea and a tearfilm break up time of 5 seconds (both eyes).
  • Schirmer's test results were 5 mm (right eye) and 10 mm (left eye).
  • Use of a sodium hyaluronate based lubricant (Hyloparin) and a vitamin A eye ointment as needed represented the established therapeutic regime.
  • aqueous ophthalmic solution with a pH of 6.3 comprising 0.1% w/w chitosan-NAC with a degree of modification of 210 ⁇ free thiol groups / g polymer, polyethylenglycol 40, hydroxypropyl methylcellulose and mannitol in a boric acid buffer was started. Medication with Hyloparin and the ointment as needed was continued.
  • the treatment with the chitosan-NAC solution was paused for 30 days.
  • Example 4 case study in a patient with dry eye syndrome and Morbus Crohn
  • SPK superficial punctate keratitis
  • aqueous ophthalmic solution with a pH of 6.3 comprising 0.1% w/w chitosan-NAC with a degree of modification of 210 ⁇ free thiol groups / g polymer, polyethylenglycol 40, hydroxypropyl methylcellulose and mannitol in a boric acid buffer was started. After 5 days of treatment, the application was paused for 7 days.
  • Example 5 case study in male patient with dry eyes
  • a male patient suffered from severe dry eye He applied an aqueous ophthalmic solution with a pH of 6.3 comprising 0.1% w/w chitosan-NAC with a degree of modification of 210 ⁇ free thiol groups / g polymer, polyethylenglycol 40, hydroxypropyl methylcellulose and mannitol in a boric acid buffer twice daily for a time period of 6 weeks and noted an improvement in dry eye symptoms.
  • Application was paused and resumed as needed when the patient noted a worsening of the symptoms during a time period of about 5 months.
  • Example 6 case study in female patient with dry eye symptoms
  • a female patient with dry eye symptoms applied an aqueous ophthalmic solution with a pH of 6.3 comprising 0.1% w/w chitosan-NAC with a degree of modification of 210 ⁇ free thiol groups / g polymer, polyethylenglycol 40, hydroxypropyl methylcellulose and mannitol in a boric acid buffer once daily for five consecutive days (period A of 5 days) and noted improvement in dry eye symptoms.
  • Period A of 5 days the patient continued to apply the chitosan-NAC solution once daily every third or every fourth day to maintain the improvement of dry eye symptoms (periods B/B' of 2 to 3 days; period C/C of 1 day).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une solution ophtalmique aqueuse stérile comprenant du N-(N-acétylcystéinyl-)chitosane ayant une teneur en groupes thiol libres comprise entre 80 et 280 umol/g de polymère, pour une utilisation dans le traitement d'un trouble de la cornée non infectieux, en particulier des maladies des yeux secs et des défauts épithéliaux cornéens persistants, ladite solution étant appliquée par intermittence, caractérisée par une posologie dans laquelle la solution est appliquée à l'œil pendant une période A de 5 jours ou plus, puis l'application est interrompue pendant une période B comprise entre au moins 2 jours et au plus 180 jours, puis la solution est appliquée à nouveau pendant une période C de 1 jour ou plus.
EP18722034.8A 2017-05-03 2018-05-03 Solution ophtalmique aqueuse stérile contenant du n-(n-acétylcystéinyl)-chitosane pour le traitement de troubles de la cornée non infectieux Withdrawn EP3618803A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17169249 2017-05-03
PCT/EP2018/061367 WO2018202783A1 (fr) 2017-05-03 2018-05-03 Solution ophtalmique aqueuse stérile contenant du n-(n-acétylcystéinyl)-chitosane pour le traitement de troubles de la cornée non infectieux

Publications (1)

Publication Number Publication Date
EP3618803A1 true EP3618803A1 (fr) 2020-03-11

Family

ID=58692356

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18722034.8A Withdrawn EP3618803A1 (fr) 2017-05-03 2018-05-03 Solution ophtalmique aqueuse stérile contenant du n-(n-acétylcystéinyl)-chitosane pour le traitement de troubles de la cornée non infectieux

Country Status (2)

Country Link
EP (1) EP3618803A1 (fr)
WO (1) WO2018202783A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127144A1 (fr) 2010-04-06 2011-10-13 Synedgen Inc. Procédés et compositions de traitement de blessures utilisant des composés de chitosane
CA2883704C (fr) 2012-09-20 2021-09-28 Synedgen, Inc. Procedes pour le traitement ou la prevention de dommages resultant d'un rayonnement, d'un trauma ou d'un choc

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1258781B (it) 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
AT406054B (de) 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
BRPI0722061B8 (pt) 2006-12-22 2021-06-22 Croma Pharma Ges M B H uso de um polímero contendo grupo tiol e implante
CA2721938C (fr) 2008-04-24 2016-08-09 Medtronic, Inc. Composition protectrice contenant du chitosane
CA2721985C (fr) 2008-04-24 2016-06-21 Medtronic, Inc. Gel de chitosant thiolate destine au traitement des tissus muqueux
AU2009240512B2 (en) 2008-04-24 2014-07-10 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
WO2011127144A1 (fr) 2010-04-06 2011-10-13 Synedgen Inc. Procédés et compositions de traitement de blessures utilisant des composés de chitosane
LT3139903T (lt) 2014-05-07 2019-09-10 Croma-Pharma Gesellschaft M.B.H. Vandeninis akių tirpalas ir sausų akių sindromo gydymo būdas
US10583152B2 (en) 2015-10-30 2020-03-10 Croma-Pharma Gesellschaft M.B.H. Therapeutic use of a sterile aqueous ophthalmic solution
EP3368006B1 (fr) 2015-10-30 2019-12-04 Croma-Pharma Gesellschaft m.b.H. Utilisation thérapeutique d'une solution ophtalmique aqueuse stérile

Also Published As

Publication number Publication date
WO2018202783A1 (fr) 2018-11-08

Similar Documents

Publication Publication Date Title
JP7432654B2 (ja) 人工涙液、コンタクトレンズ及び薬剤担体組成物並びにその使用方法
CA2630193C (fr) Composition pharmaceutique exempte de dexpanthenol, d'ions calcium et de phosphate, utilisation de chelateurs du calcium et d'un regulateur de viscosite acceptable sur le plan ophtalmique
EA008496B1 (ru) Офтальмологический препарат для профилактики и лечения болезненных состояний глаз
EP3618803A1 (fr) Solution ophtalmique aqueuse stérile contenant du n-(n-acétylcystéinyl)-chitosane pour le traitement de troubles de la cornée non infectieux
EP4371613A2 (fr) Composés destinés à être utilisés dans le traitement de la douleur oculaire
JP2022511335A (ja) 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法
JP6817300B2 (ja) 滅菌水性点眼液の治療的使用
US10813943B2 (en) Therapeutic use of a sterile aqueous ophthalmic solution
KR20190071674A (ko) 안과용 제제 및 안과용 약
WO2010107069A1 (fr) Composition ophtalmique contenant des acides aminés
JP2021512847A (ja) キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤
US11147831B2 (en) Agent for improving ocular subjective symptoms and method thereof
US20200121712A1 (en) Agent to be applied to ophthalmic device
WO2023048174A1 (fr) Agent thérapeutique pour maladie de la cornée
Kasetsuwan et al. A sodium hyaluronate ophthalmic solution for reducing dry eye and enhancing corneal wound healing after photorefractive keratectomy
Jaanus Preparations for the Dry Eye

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOELLER, SONJA

Inventor name: HORNOF, MARGIT

Inventor name: PRINZ, MARTIN

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 51/06 20060101ALI20201022BHEP

Ipc: A61P 27/02 20060101ALI20201022BHEP

Ipc: A61K 47/26 20060101ALI20201022BHEP

Ipc: A61K 9/00 20060101AFI20201022BHEP

Ipc: A61K 47/61 20170101ALI20201022BHEP

Ipc: A61K 47/38 20060101ALI20201022BHEP

Ipc: A61K 9/08 20060101ALI20201022BHEP

Ipc: A61P 27/04 20060101ALI20201022BHEP

Ipc: A61K 47/36 20060101ALI20201022BHEP

Ipc: A61K 47/10 20170101ALI20201022BHEP

INTG Intention to grant announced

Effective date: 20201117

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
17Q First examination report despatched

Effective date: 20210407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211126